United States & Kyowa Kirin
6 shared events · Importance 3 · Last updated Sep 04, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Domestic
United States: The U.S. government, through the United States — White House, negotiated the drug pricing deals to lower costs for patients and reduce federal spending. The agreements are part of a broader push to make healthcare more affordable.
Kyowa Kirin: Kyowa Kirin agreed to MFN pricing and plans to increase U.S. manufacturing, aiming to supply over 95% of its U.S.-manufactured drugs to American patients within two years.
Aug 18, 2026 · 37 articles
Business
United States: The United States is involved in geopolitical tensions with Iran and the Houthis, affecting global markets and oil prices.
Kyowa Kirin: Kyowa Kirin was down almost 3% on one day, reflecting losses.
Jul 24, 2026 · 37 articles
Business
United States: The U.S. was involved in geopolitical tensions with Iran, impacting global markets.
Kyowa Kirin: Kyowa Kirin declined almost 4%, underperforming the market.
Apr 21, 2022 · 26 articles
Tech
United States: The United States is mentioned as a country where the drug POTELIGEO is indicated for treatment, and where adverse reactions can be reported to the FDA.
Kyowa Kirin: Kyowa Kirin announced positive results from its PROSPER study for mogamulizumab, which is expected to positively impact its stock price and reputation.
Jun 29, 2026 · 7 articles
Tech
United States: The U.S. indication for POTELIGEO (mogamulizumab-kpkc) is mentioned, indicating the drug's availability and regulatory status in the country.
Kyowa Kirin: Kyowa Kirin funded the research and developed mogamulizumab, a drug that showed improved survival outcomes in patients with rare blood cancers, positively impacting the company's reputation and potential market position for its product POTELIGEO.
Jun 30, 2026 · 6 articles
Business
United States: The United States is a key market for Stivarga, where loss of exclusivity is anticipated in 2030 and where regulatory approval for the deal is required.
Kyowa Kirin: Kyowa Kirin is referenced as the former joint venture partner of Grunenthal Meds, whose full ownership Grunenthal acquired earlier in 2026, illustrating Grunenthal's ongoing M&A strategy.
Sep 21, 2026 · 6 articles
80
Kyowa Kirin signed drug pricing deal United StatesTrump announces nine new...
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Kyowa Kirin interact across events, view sentiment trends, and discover connected entities.
Open Dashboard